A PricewaterhouseCoopers report has highlighted the directions that the growth of the contract development and manufacturing organisation (CDMO) outsourcing market will take in the near future.
List view / Grid view
Filter the results
The CDMO AMRI has said it will boost its production of the malaria drug hydroxychloroquine sulfate, identified as a potential COVID-19 treatment, following an emergency use authorisation from the FDA.
The market for containment facilities and containment manufacturing will increase in the future, due to a growing demand for oncology treatments.
Since 2014, AMRI has significantly expanded its service and product range through several acquisitions. Today, it has more than 3,100 employees at 27 locations in the US, UK, Europe and Asia, and it continues to seek new opportunities in areas of complex science. William S Marth, President and Chief Executive…
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
19 February 2014 | By Dr Xufeng Sun, Senior Research Scientist II, AMRI
Dr Xufeng Sun, Senior Research Scientist II at AMRI, discusses their SMARTSOURCING™ approach, looking particularly at the use of Raman technology...
As regulatory expectations continue to evolve in the area of pharmaceutical development, working with contract research and manufacturing organizations that couple execution experience with high-end technical capabilities and contemporary quality systems will ensure the most value from strategic partnerships and enhance a project’s progress on its path toward commercialization.
Founded in 1991, AMRI (Albany Molecular Research Inc.) is a contract research and manufacturing organisation, with locations in the US, Europe and Asia. The company provides fully integrated drug discovery, development and manufacturing services to the pharmaceutical and biotechnology industries.